Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group - PubMed (original) (raw)
Clinical Trial
. 2000 May 27;355(9218):1845-50.
doi: 10.1016/s0140-6736(00)02288-1.
Affiliations
- PMID: 10866439
- DOI: 10.1016/s0140-6736(00)02288-1
Clinical Trial
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group
K G Nicholson et al. Lancet. 2000.
Erratum in
- Lancet 2000 Nov 25;356(9244):1856
Abstract
Background: Use of some antiviral drugs for influenza infection is limited by potential rapid emergence of resistance. We studied the efficacy and safety of oseltamivir, the oral prodrug of the neuraminidase inhibitor GS4071, in adults with naturally acquired laboratory-confirmed influenza.
Methods: We did a randomised controlled trial of 726 previously healthy non-immunised adults with febrile influenza-like illness of up to 36 h duration. Patients were assigned oral oseltamivir 75 mg (n=243), oseltamivir 150 mg (n=245), or placebo (n=238) twice daily for 5 days. We assessed recovery by questionnaire and temperature recordings. The primary endpoint was time to resolution of illness in influenza-infected patients.
Findings: 475 (66%) patients had confirmed infection. Duration of illness was significantly shorter by 29 h (25% reduction, median duration 87.4 h [95% CI 73.3-104.7], p=0.02) with oseltamivir 75 mg and by 35 h (30%, 81.8 h [68.2-100.0], p=0.01) with oseltamivir 150 mg than with placebo (116.5 h [101.5-137.8]). The effect of oseltamivir was apparent within 24 h of the start of treatment. In patients treated within 24 h of symptom onset, symptoms were alleviated 43 h (37% reduction) and 47 h (40%) earlier with oseltamivir 75 mg and 150 mg, respectively, compared with placebo (75 mg 74.5 h [68.2-98.0], p=0.02; 150 mg 70.7 h [54.0-89.4], p=0.01; placebo 117.5 h [103.0-143.8]). Oseltamivir was associated with lower [corrected] symptom scores, less viral shedding, and improved health, activity, and sleep quality, and was well tolerated.
Interpretation: Oseltamivir was effective and well tolerated in the treatment of natural influenza infection in adults. The efficacy, tolerability, and ease of administration warrant further investigation in children, elderly patients, and at-risk patients.
Similar articles
- Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.
Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Singh S, Kinnersley N, Ward P, Mills RG. Treanor JJ, et al. JAMA. 2000 Feb 23;283(8):1016-24. doi: 10.1001/jama.283.8.1016. JAMA. 2000. PMID: 10697061 Clinical Trial. - Oseltamivir: a review of its use in influenza.
McClellan K, Perry CM. McClellan K, et al. Drugs. 2001;61(2):263-83. doi: 10.2165/00003495-200161020-00011. Drugs. 2001. PMID: 11270942 Review. - [Clinical efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir in treating acute influenza--placebo-controlled double-blind multicenter phase III trial].
Kashiwagi S, Kudoh S, Watanabe A, Yoshimura I. Kashiwagi S, et al. Kansenshogaku Zasshi. 2000 Dec;74(12):1044-61. doi: 10.11150/kansenshogakuzasshi1970.74.1044. Kansenshogaku Zasshi. 2000. PMID: 11193557 Clinical Trial. Japanese. - Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
Fry AM, Goswami D, Nahar K, Sharmin AT, Rahman M, Gubareva L, Azim T, Bresee J, Luby SP, Brooks WA. Fry AM, et al. Lancet Infect Dis. 2014 Feb;14(2):109-18. doi: 10.1016/S1473-3099(13)70267-6. Epub 2013 Nov 22. Lancet Infect Dis. 2014. PMID: 24268590 Clinical Trial. - Neuraminidase inhibitors for preventing and treating influenza in children.
Matheson NJ, Symmonds-Abrahams M, Sheikh A, Shepperd S, Harnden A. Matheson NJ, et al. Cochrane Database Syst Rev. 2003;(3):CD002744. doi: 10.1002/14651858.CD002744. Cochrane Database Syst Rev. 2003. PMID: 12917931 Updated. Review.
Cited by
- Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system.
Li Y, Wang X, Liao Y, Zeng Y, Lin W, Zhuang W. Li Y, et al. BMC Infect Dis. 2024 May 9;24(1):446. doi: 10.1186/s12879-024-09339-4. BMC Infect Dis. 2024. PMID: 38724914 Free PMC article. - [Guidelines for the management of community pneumonia in adult who needs hospitalization].
Álvarez-Rocha L, Alós JI, Blanquer J, Álvarez-Lerma F, Garau J, Guerrero A, Torres A, Cobo J, Jordá R, Menéndez R, Olaechea P, Rodríguez de Castro F; Grupo de Estudio de la Neumonía Comunitaria Grave. Álvarez-Rocha L, et al. Med Intensiva. 2005 Feb;29(1):21-62. doi: 10.1016/S0210-5691(05)74199-1. Epub 2009 Jan 6. Med Intensiva. 2005. PMID: 38620135 Free PMC article. Spanish. - Retracted and republished from: "The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs".
Li Y, Huo S, Yin Z, Tian Z, Huang F, Liu P, Liu Y, Yu F. Li Y, et al. mBio. 2024 May 8;15(5):e0017524. doi: 10.1128/mbio.00175-24. Epub 2024 Mar 29. mBio. 2024. PMID: 38551343 Free PMC article. - Symptomatic Differences between Influenza A/H3N2 and A/H1N1 in Korea.
Lee HJ, Ryu G, Lee KI. Lee HJ, et al. J Clin Med. 2023 Aug 30;12(17):5651. doi: 10.3390/jcm12175651. J Clin Med. 2023. PMID: 37685717 Free PMC article. - Efficient symptomatic treatment and viral load reduction for children with influenza virus infection by nasal-spraying Bacillus spore probiotics.
Tran TT, Phung TTB, Tran DM, Bui HT, Nguyen PTT, Vu TT, Ngo NTP, Nguyen MT, Nguyen AH, Nguyen ATV. Tran TT, et al. Sci Rep. 2023 Sep 8;13(1):14789. doi: 10.1038/s41598-023-41763-5. Sci Rep. 2023. PMID: 37684332 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials